This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
scenario 1, 75% of "life-threatening" calls to receive an ambulance response within 8 minutes; scenario 2, 75th percentile of distribution of DTN time for thrombolysis is 30 minutes (with the existing proportion of patients receiving thrombolysis); scenario 3, 75th percentile of distribution of DTN time for thrombolysis is 20 minutes (with the existing proportion of patients receiving thrombolysis); scenario 4, 75th percentile of distribution of DTN time for thrombolysis is 30 minutes (including the additional eligible patients (10% of the total) who currently fail to receive thrombolysis); and scenario 5, a combination of scenarios 1 and 2.
Outcomes assessed in the review
The outcomes estimated from the literature were:
the probabilities of transitions across health states; the proportion of patients experiencing cardiac arrests or MIs; the percentage of patients discharged (survival rate to hospital discharge) given different ambulance response times; 
Study designs and other criteria for inclusion in the review
The authors stated that a search was conducted to identify the best evidence with which to populate the decision model. However, few details of the review and the primary studies were reported. Much of the data were extracted from three datasets: Heartstart Scotland (1991-98), the United Kingdom Heart Attack Study and the West Midlands Thrombolysis Project . Thrombolysis efficacy data came from a meta-analysis.
Sources searched to identify primary studies
MEDLINE, the Cochrane Library, EMBASE and grey literature were searched for relevant primary studies.
Criteria used to ensure the validity of primary studies
The use of large, national databases and a meta-analysis should improve the validity of the primary estimates.
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Five primary studies provided the clinical data. 
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The proportion of patients experiencing cardiac arrests or MIs was 61%.
The percentage of patients discharged (survival rate to hospital discharge) was 14.7% for an ambulance response time of 0 -4 minutes, 9.2% for a response time of 4 -8 minutes, 5.1% for a response time of 8 -12 minutes, and 4.3% for a response time of at least 12 minutes.
The percentage of patients at baseline responded to in the time interval was 12.2% for an ambulance response time of 0 -4 minutes, 42.9% for a response time of 4 -8 minutes, 28.8% for a response time of 8 -12 minutes, and 16.1% for a response time of at least 12 minutes.
The percentage of patients at each time interval achieving the NSF ambulance targets was 22.1% for an ambulance response time of 0 -4 minutes, 52.9% for a response time of 4 -8 minutes, 17.1% for a response time of 8 -12 minutes, and 7.9% for a response time of at least 12 minutes.
The proportion of patients at hospital arrival with a diagnosis of MI and receiving thrombolysis was about 50%.
In terms of thrombolysis efficacy, a relative mortality risk of 0.70 was associated with a time interval (from onset of symptoms to administration of thrombolysis) of up to 1 hour. The relative mortality risk was 0.74 for a time interval of 2 -3 hours, 0.79 for 4 -6 hours, 0.85 for 7 -12 hours, and 0.98 for more than 12 hours.
The percentage of patients reaching different DTN times at baseline was 29.8% for a time of 0 -29 minutes, 33.7% for a time of 30 -59 minutes, 24.9% for a time of 59 -119 minutes, 8.8% for a time of 120 -239 minutes, and 2.5% for a time of 240 minutes or longer.
The percentage of patients at each DTN time interval achieving the NSF thrombolysis targets was 75.3% for a time of 0 -29 minutes, 18.1% for a time of 30 -59 minutes, 4.9% for a time of 59 -119 minutes, 1.1% for a time of 120 -239 minutes, and 0.6% for a time of 240 minutes or longer.
Measure of benefits used in the economic analysis
The summary benefit measure was the number of CHD life-years saved with each intervention in comparison with standard care. This was obtained using a modelling approach. An annual discount rate of 3.5% was applied. The number of deaths prevented in each scenario was also reported.
Direct costs
The analysis of the costs was conducted from the perspective of the NHS. It included the costs associated with improving ambulance response time and the costs of thrombolytic drug treatment (streptokinase and alteplase). A breakdown of the cost items was not provided, and the unit costs and the quantities of resources used were not presented separately. The costs and resource use data for ambulance services were estimated using data from the Review of Ambulance Performance Standards, which estimated the cost associated with attaining a 75% ambulance response time within 8 minutes. These costs were compared with the actual costs spent by the Department of Health on improving ambulance response times. The costs of thrombolytic drug treatment were taken from the British National Formulary. Some assumptions were made to identify the optimal strategies to reduce time to thrombolysis. Discounting was relevant, as the costs were incurred during a 20-year timeframe, and an annual rate of 3.5% was applied. The price year was 2000.
